Mumbai: Venus Remedies has secured marketing authorization for docetaxel from Israel and cytarabine from Colombia, While docetaxel, an antineoplastic agent, is beneficial in the treatment of breast, prostate, head, neck and non-small cell lung cancer, cytarabine is useful in acute non-lymphocytic leukaemia, acute lymphocytic leukaemia and chronic myelocytic leukaemia.
Israel’s pharmaceutical market, valued at about $5 billion, is projected to grow at a five-year compound annual growth rate (CAGR) of 4.2 per cent up to 2026. Israel has a dynamic pharmaceutical expanse known for its innovation and commitment to healthcare excellence. The marketing authorization for cytarabine from Colombia, on the other hand, marks a significant expansion of Venus Remedies in the Latin American market. Colombia, the third-largest pharmaceutical market in South America projected to grow at a five-year CAGR of 3.1 per cent up to 2026, has emerged as a vital player in the pharmaceutical industry, exhibiting robust growth and fostering innovation. The Colombian market dominated by oncology drugs has witnessed steady expansion.
Saransh Chaudhary, CEO, Venus Medicine Research Center (VMRC), said, “We are excited about the prospect of bringing these advanced therapies to patients in Israel and Colombia, and we remain committed to exploring new frontiers in healthcare that align with our vision of a healthier world,” he said.
Aditi K Chaudhary, President, International Business, Venus Remedies, said, “These marketing approvals mark a significant stride in our global mission to enhance healthcare accessibility. One of the largest exporters of docetaxel, Venus Remedies is proud to include Israel in the list of countries it supplies docetaxel to, including Malaysia, Namibia, Myanmar, PanamaIndonesia, Iraq, Tanzania, Germany, and Zimbabwe. Likewise, the market reach of Venus Remedies for cytarabine extends to Guinea-Bissau, Jordan, Namibia, Oman, Saudi Arabia, Tunisia and Venezuelabesides Colombia.”
